OBJECTIVE: Peripheral blood mononuclear cells (PBMCs) in systemic lupus erythematosus (SLE) patients exhibit a gene expression program (interferon [IFN] signature) that is attributed to overproduction of type I IFNs by plasmacytoid dendritic cells. Type I IFNs have been thought to play a role in the pathogenesis of SLE. This study was undertaken to examine an unexpected influence of monocyte/macrophages on the IFN signature. METHODS: Proinflammatory (classic) and antiinflammatory (nonclassic) monocyte/macrophages were sorted from mice and analyzed by RNA sequencing and quantitative polymerase chain reaction (qPCR). Type I IFN-α/β/ω receptor (IFNAR-1) expression was determined by qPCR and flow cytometry. Macrophages were stimulated in vitro with IFNα, and pSTAT1was measured. RESULTS: Transcriptional profiling of peritoneal macrophages from mice with pristane-induced SLE unexpectedly indicated a strong IFN signature in classic, but not nonclassic, monocyte/macrophages exposed to the same type I IFN concentrations. Ifnar1 messenger RNA and IFNAR surface staining were higher in classic monocyte/macrophages versus nonclassic monocyte/macrophages (P < 0.0001 and P < 0.05, respectively, by Student's t-test). Nonclassic monocyte/macrophages were also relatively insensitive to IFNα-driven STAT1 phosphorylation. Humans exhibited a similar pattern: higher IFNAR expression (P < 0.0001 by Student's t-test) and IFNα-stimulated gene expression (P < 0.01 by paired Wilcoxon's rank sum test) in classic monocyte/macrophages and lower levels in nonclassic monocyte/macrophages. CONCLUSION: This study revealed that the relative abundance of different monocyte/macrophage subsets helps determine the magnitude of the IFN signature. Responsiveness to IFNα signaling reflects differences in IFNAR expression in classic (high IFNAR) compared to nonclassic (low IFNAR) monocyte/macrophages. Thus, the IFN signature depends on both type I IFN production and the responsiveness of monocyte/macrophages to IFNAR signaling.
OBJECTIVE: Peripheral blood mononuclear cells (PBMCs) in systemic lupus erythematosus (SLE) patients exhibit a gene expression program (interferon [IFN] signature) that is attributed to overproduction of type I IFNs by plasmacytoid dendritic cells. Type I IFNs have been thought to play a role in the pathogenesis of SLE. This study was undertaken to examine an unexpected influence of monocyte/macrophages on the IFN signature. METHODS: Proinflammatory (classic) and antiinflammatory (nonclassic) monocyte/macrophages were sorted from mice and analyzed by RNA sequencing and quantitative polymerase chain reaction (qPCR). Type I IFN-α/β/ω receptor (IFNAR-1) expression was determined by qPCR and flow cytometry. Macrophages were stimulated in vitro with IFNα, and pSTAT1was measured. RESULTS: Transcriptional profiling of peritoneal macrophages from mice with pristane-induced SLE unexpectedly indicated a strong IFN signature in classic, but not nonclassic, monocyte/macrophages exposed to the same type I IFN concentrations. Ifnar1 messenger RNA and IFNAR surface staining were higher in classic monocyte/macrophages versus nonclassic monocyte/macrophages (P < 0.0001 and P < 0.05, respectively, by Student's t-test). Nonclassic monocyte/macrophages were also relatively insensitive to IFNα-driven STAT1 phosphorylation. Humans exhibited a similar pattern: higher IFNAR expression (P < 0.0001 by Student's t-test) and IFNα-stimulated gene expression (P < 0.01 by paired Wilcoxon's rank sum test) in classic monocyte/macrophages and lower levels in nonclassic monocyte/macrophages. CONCLUSION: This study revealed that the relative abundance of different monocyte/macrophage subsets helps determine the magnitude of the IFN signature. Responsiveness to IFNα signaling reflects differences in IFNAR expression in classic (high IFNAR) compared to nonclassic (low IFNAR) monocyte/macrophages. Thus, the IFN signature depends on both type I IFN production and the responsiveness of monocyte/macrophages to IFNAR signaling.
Authors: Dina C Nacionales; Kindra M Kelly; Pui Y Lee; Haoyang Zhuang; Yi Li; Jason S Weinstein; Eric Sobel; Yoshiki Kuroda; Jun Akaogi; Minoru Satoh; Westley H Reeves Journal: Am J Pathol Date: 2006-04 Impact factor: 4.307
Authors: Yi Li; Pui Y Lee; Erinn S Kellner; Matthew Paulus; Juliana Switanek; Yuan Xu; Haoyang Zhuang; Eric S Sobel; Mark S Segal; Minoru Satoh; Westley H Reeves Journal: Arthritis Res Ther Date: 2010-05-18 Impact factor: 5.156
Authors: Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Isaac Hurtado-Guerrero; Maria Jesús Pinto-Medel; Patricia Urbaneja; Jose Luis Rodriguez-Bada; Antonio León; Miguel Guerrero; Óscar Fernández; Laura Leyva; Begoña Oliver-Martos Journal: PLoS One Date: 2017-01-19 Impact factor: 3.240
Authors: Pui Y Lee; David B Sykes; Sarah Ameri; Demetrios Kalaitzidis; Julia F Charles; Nathan Nelson-Maney; Kevin Wei; Pierre Cunin; Allyn Morris; Astrid E Cardona; David E Root; David T Scadden; Peter A Nigrovic Journal: Sci Immunol Date: 2017-05-26
Authors: Bas D Koster; Marta López González; Mari Fcm van den Hout; Annelies W Turksma; Berbel Jr Sluijter; Barbara G Molenkamp; Paul Am van Leeuwen; Saskia Vosslamber; Rik J Scheper; Alfons Jm van den Eertwegh; M Petrousjka van den Tol; Ekaterina J Jordanova; Tanja D de Gruijl Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751